Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
European Urology|August 18, 1999
PSA decline is an independent prognostic marker in hormonally treated prostate cancerC Palmberg, P Koivisto, T Visakorpi, et al.
The American Journal of Pathology|July 17, 1998
Genetic alterations in hormone-refractory recurrent prostate carcinomasN N Nupponen, L Kakkola, P Koivisto, et al.
The American Journal of Pathology|January 9, 1998
Androgen receptor gene and hormonal therapy failure of prostate cancerP Koivisto, M Kolmer, T Visakorpi, et al.
The American Journal of Pathology|September 1, 1994
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridizationT Visakorpi, E Hyytinen, A Kallioniemi, et al.
Cancer Gene Therapy|March 27, 2001
Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapyS Loimas, M R Toppinen, T Visakorpi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 1, 1992
Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomasT Visakorpi, O P Kallioniemi, T Koivula, et al.
Journal of the National Cancer Institute|June 3, 1992
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulationT Visakorpi, O P Kallioniemi, A Heikkinen, et al.
The Journal of Pathology|January 12, 2000
Androgen receptor gene mutations in hormone-refractory prostate cancerM J Wallén, M Linja, K Kaartinen, et al.
Pageof 8